Asunto(s)

Betametasona/uso terapéutico , Madurez de los Órganos Fetales/efectos de los fármacos , Recien Nacido Prematuro , Femenino , Humanos , Recién Nacido , Pulmón/embriología , Metronidazol , Embarazo

RESUMEN

Metronidazole pharmacokinetics and tissue distribution were studied in 11 infants varying in gestational age from 28 to 40 weeks. Elimination half-life was inversely related to gestational age, and ranged from 22.5 to 109 hours. Hepatic hydroxylation of metronidazole was not evident in infants less than 35 weeks' gestation, unless they had been exposed prenatally to betamethasone. A dosage schedule of 15 mg/kg intravenously as an initial single dose is proposed, and will provide adequate therapeutic levels for 48 hours in the preterm infant and for 24 hours in the term infant. Subsequently a dose of 7.5 mg/kg/12 hours is suggested for the first week of life.

Asunto(s)

Infecciones Bacterianas/tratamiento farmacológico , Enfermedades del Recién Nacido/tratamiento farmacológico , Metronidazol/metabolismo , Betametasona/uso terapéutico , Femenino , Edad Gestacional , Semivida , Humanos , Recién Nacido , Infusiones Parenterales , Cinética , Masculino , Metronidazol/administración & dosificación , Embarazo , Efectos Tardíos de la Exposición Prenatal , Distribución Tisular